Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy

Acharya, Sarbari; Dilnawaz, Fahima; Sahoo, Sanjeeb K.

doi:10.1016/j.biomaterials.2009.07.008

Cited by 307 publications

(221 citation statements)

References 53 publications

Supporting

Mentioning

216

Contrasting

Order By: Relevance

“…Conjugation by carbodiimide chemistry of an EGFR-antibody to the surface of polymeric poly(lactide-coglycolide) nanoparticles loaded with rapamycin has been used to selectively target the extracellular ligand binding domain of EGFR [515]. This approach showed an enhanced antiproliferative activity over the same nanoparticles without the targeting moiety and over free rapamycin, being observed an increased uptake on malignant MCF-7 breast cancer cells by confocal microscopy and fluorescence spectroscopy.…”

Section: Monoclonal Antibodies-based Targetingmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,465

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: Monoclonal Antibodies-based Targetingmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,465

754

View full text Add to dashboard Cite

show abstract

“…Also it has been found to play an important role in the progression of several human malignancies. Human epidermal receptor-2 (HER-2) is reported to be expressed in 14-91% of patients with breast cancer (Scaltriti and Baselga, 2006;Acharya et al, 2009;Danhier et al, 2010). EGFR is expressed or over expressed in a diversity of solid tumors, including colorectal cancer, non-small cell lung cancer and squamous cell carcinoma of the head and neck, as well as ovarian, kidney, pancreatic, and prostate cancer (Lurje and Lenz, 2009;Danhier et al, 2010).…”

Section: The Targeting Of Cancer Cellmentioning

confidence: 99%

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Mirakabad

Nejati-Koshki²,

Akbarzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

408

154

View full text Add to dashboard Cite

“…One of the greatest challenges is defining the ideal targeting agent or agents to selectively and effectively transport nanoparticle structures in cancerous tissue [26,27]. Generated smart agents with drug delivery and molecular targeting capabilities, developed by loading nanoparticles using antibodies is also accounted a therapeutic approach for breast cancer therapy [26,27].…”

Section: Nanoparticles For Therapy Breast Cancermentioning

confidence: 99%

“…Generated smart agents with drug delivery and molecular targeting capabilities, developed by loading nanoparticles using antibodies is also accounted a therapeutic approach for breast cancer therapy [26,27]. Doxorubicin has been framed with a liposome delivery system into nanoparticle, it was shown that the compound preserves the efficacy of the drug and reduces cardiac toxic effects [28].…”

Section: Nanoparticles For Therapy Breast Cancermentioning

confidence: 99%

Breast cancer: early diagnosis and effective treatment by drug delivery tracing

Shamsi

Islamian

2017

Nucl. Med. Rev.

View full text Add to dashboard Cite

Breast cancer is the most frequent cancer in women and it is the main reason of cancer-related deaths of women worldwide.Different types of breast cancer diagnostic examinations are also available, such as mammography, MRI, biopsy, ultrasound and molecular imaging. Radionuclide-based imaging methods including SPECT and PET are useful in early diagnosis and treatment of the cancer. The radiolabeling of chemo drugs with nanoparticles should be recommended from the standpoint of an early diagnosis and effective treatment of breast cancer.

show abstract

Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy

Cited by 307 publications

References 53 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Breast cancer: early diagnosis and effective treatment by drug delivery tracing

Contact Info

Product

Resources

About